Triiodothyronine hormone supplementation therapy in septic shock patients with euthyroid sick syndrome: two pilot, placebo-controlled, randomized trials - 15/01/24
, Visnja Nesek Adam c, d, e , Senada Causevic a, b Abstract |
Background |
To assess 28-day survival in two pilot groups of septic shock patients with euthyroid sick syndrome (ESS) supplemented with triiodothyronine (T3).
Methods |
A total of 95 septic shock patients with ESS were divided according to values of the thyroid hormones into low T3 and low T3T4 groups. Among 48 patients with low T3, 24 (50%) were randomized to T3 for 4 days and 24 (50%) to placebo. Among 47 patients with low T3T4, 24 (51%) were randomized to T3 for 4 days and 23 (49%) to placebo. The analysis included 28-day survival as the primary outcome and laboratory with hemodynamics as the secondary outcomes. Laboratory data were analyzed on the day of admission (T0), on the first (T1), third (T2) and seventh day (T3) with hemodynamics analyzed for the first four days.
Results |
In the low T3 population, 18 (75%) patients receiving T3 died at day 28 compared with 8 (33.3%) patients receiving placebo (p = 0.004). In the low T3T4 population, 6 (25%) patients receiving T3 died in ICU compared with 12 (52.1%) patients receiving placebo (p = 0.039). Oral T3 treatment increased mean arterial pressure values at day 1, day 3 and day 7 in the low T3T4 population, (p = 0.015, =0.005 and =0.042 respectively), and had no significant effect on these values in the low T3 population.
Conclusion |
T3 supplementation was associated with a low 28-day mortality rate in patients with low T3T4 but with increased mortality in patients with low T3 ESS. These results suggest caution before initiating thyroid supplementation in septic patients.
Registration |
ClinTrials.gov (NCT05270798).
Le texte complet de cet article est disponible en PDF.Abbreviations : T3, ESS, NTIS, ICU, MAP, T4, rT3, TSH, TRH, APACHE II, SAPS II, SOFA, ETI, HBP, DM, FT3, CVD, FT4, NLR, PLR, PI, mGPS, VDI, SI, mITT, MV
Keywords : Septic shock, Euthyroid sick syndrome, Triiodothyronine supplementation
Plan
Vol 43 - N° 2
Article 101336- avril 2024 Retour au numéro
Article précédent
- Risk factors for poor performance in finger cuff non-invasive monitoring of arterial pressure: A prospective multicenter study
- Karim Lakhal, Jérôme E. Dauvergne, Hélène Messet-Charriere, Mai-Anh Nay, Toufik Kamel, Grégoire Muller, Vincent Robert-Edan, Bertrand Rozec, Stephan Ehrmann, Sophie Jacquier, Thierry Boulain
- Pulmonary embolism impacts clinical outcomes of intubated patients with acute respiratory distress syndrome related to COVID-19
- Steve Primmaz, Tommaso Rochat Negro, Noémie Suh, Christophe Le Terrier, Hannah Wozniak, Jérôme Pugin, Karim Bendjelid
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?